Estrogen
As of the edition of 20 October 2026, Estrogen is a small molecule: in active development; acts on ESR1 and ESR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 63, 7 stopped early
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Mental health; Nutrition and metabolism; Nervous system; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Estrogen.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 21 | 11 | 3 | 4 |
| Phase 1 | 3 | 2 | 1 | 0 |
| Phase 2 | 12 | 6 | 4 | 0 |
| Phase 3 | 12 | 8 | 1 | 2 |
| Phase 4 | 15 | 8 | 5 | 1 |
| All trials | 63 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Novo Nordisk | Lead sponsor of trials | 1989 to now |
| Eli Lilly | Lead sponsor of trials | 2002 to now |
| Bayer | Lead sponsor of trials | 2026 to now |